The targeted therapy bezuclastinib was safe and rapidly reduced markers of disease burden while also improving symptoms for patients with a rare blood disorder called nonadvanced system mastocytosis, according to results of the Phase II SUMMIT trial reported by researchers at The University of Texas MD Anderson Cancer Center.
Michigan voters backed abortion rights. Now Democrats want to go further.
Nearly every day, Halley Crissman and her physician colleagues in Michigan must tell patients seeking abortions they’re very sorry that they can’t proceed with their
October 17, 2023